Clinical Trial

Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care

Study acronym: PRiMAL
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-02-14; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2026-03-04
Status change: Not Yet Recruiting → Recruiting 2022-04-13
Trial Details
NCT Number NCT05254795
Lead Sponsor Timothy Mullett
Collaborators: Eli Lilly and Company
Conditions Non-Small Cell Lung Cancer
Enrollment 659 participants
Start Date 2022-04-13
Primary Completion 2026-12-22 (estimated)
Study Completion 2026-12-22 (estimated)
Updated on ClinicalTrials.gov 2026-03-06